Titan Group now offers Drug Enforcement Administration (DEA) controlled substances solutions to new and existing Vertical Vet members. The partnership provides exclusive access to Titan’s suite of services, designed to reduce risk, remediate issues, and educate personnel on how to prepare for DEA audits and inspections as well as prevent and detect internal and external drug diversion activity, according to Titan. “Our goal is to provide the veterinary industry with proactive controlled substances compliance solutions that are easy to implement and sustain long term,” said Jack Teitelman, Titan founder and CEO. “Every veterinary practice handling controlled substances is at risk for noncompliance. Inadequate security and failure to prevent drug diversion can cost a practice in lost inventory, damage to reputation, and potential physical harm to staff and patients. In the current world of widespread opioid abuse, both internal and external drug diversion threats are continuing to increase. Sadly, many unsuspecting practices remain in the dark until their drugs are stolen or missing.” In addition, the partnership offers exclusive discounts on DEA risk inspections and audits to members. Access to educational resources, including webinars, industry-accredited CLE courses, and compliance training modules, also are available as part of the partnership. “We believe that by giving members access to much-needed compliance services, education, and training, we can help practices reduce risk by teaching veterinary professionals how to detect existing issues and prevent new ones from arising,” said John Wagoner, Vertical Vet co-founder and president. Vertical Vet is offering free trial memberships to qualified veterinary practices now through the end of 2018. Visit verticalvet.com for more information.
